NOVARTIS

Novartis announces EC approval of Kisqali for early breast cancer, based on NATALEE trial results showing 25.1% reduction in recurrence risk. The approval addresses a key unmet need for patients at high risk of cancer return.

Novartis to present over 65 abstracts at ASH and SABCS, highlighting commitment to cancer and blood disorder treatments, with an art exhibit at SABCS featuring personal breast cancer stories.

Top global pharma companies excel in R&D, pipeline management, and capital allocation, leveraging AI, personalized medicine, and supply chain resilience. Leaders like Roche and Novo Nordisk face challenges in valuation, access vs. profitability, and innovation pipeline management, emphasizing the need for balanced strategies and portfolio diversification.

Novartis presents over 65 abstracts at ASH and SABCS, highlighting new data on Scemblix, Kisqali, and other treatments, emphasizing commitment to cancer and blood disorder patients. The company also showcases personal breast cancer stories at SABCS, aiming to uplift and unite the community.

The FDA approved Imkeldi, a new Imatinib oral formulation by Shorla Oncology, for 10 new indications in leukemias and other cancers in pediatric and adult patients. Imkeldi, a tyrosine kinase inhibitor, offers precise dosing and is a convenient alternative for patients with swallowing difficulties. Indications include Ph+ CML, Ph+ ALL, MDS/MPD, and GIST. Common adverse reactions include edema, nausea, and vomiting. Liver function and hematologic toxicity should be monitored, and grapefruit juice and breastfeeding are contraindicated.

The FDA approved an oral solution of imatinib (Imkeldi; Shorla Oncology) for treating certain leukemias and cancers, marking the first oral liquid form of imatinib for cancer treatment. This flavored, stable formulation, containing 80 mg of imatinib per milliliter, aims to improve dosing accuracy and patient adherence. Imatinib, initially approved in 2001 for chronic myeloid leukemia, now has expanded indications including Ph+ CML, Ph+ ALL, myelodysplastic/myeloproliferative diseases, and others. Common adverse events include edema, nausea, and fatigue, with more severe risks like hematologic toxicities and dermatologic issues.

The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.

Neuroendocrine Tumors Market to grow at 5.1% CAGR (2020-2034) driven by upcoming therapies, rising incident cases, and increased research. Key players include Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size in 6MM.

The Global Neurology Clinical Trials Market is projected to reach USD 5,549.3 million by 2024 and USD 9,231.2 million by 2033 at a CAGR of 5.8%. The market includes treatments for Alzheimer's, Parkinson's, and Huntington's diseases, driven by increased research funding, stem cell therapies, genetic advancements, and AI in trial management. The US market, valued at USD 2,244.8 million in 2024, is expected to grow to USD 3,618.9 million by 2033 at a CAGR of 5.4%. Key players include Novartis, Covance, Medpace, and Charles River Laboratories. Recent trends highlight gene therapies, AI adoption, and growing collaborations.